

S 1186

Lower Drug Costs for Families Act

Congress: 119 (2025–2027, Current)

Chamber: Senate

Policy Area: Health

Introduced: Mar 27, 2025

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Mar 27, 2025)

Official Text: <https://www.congress.gov/bill/119th-congress/senate-bill/1186>

Sponsor

Name: Sen. Cortez Masto, Catherine [D-NV]

Party: Democratic • **State:** NV • **Chamber:** Senate

Cosponsors (12 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Mar 27, 2025
Sen. Blumenthal, Richard [D-CT]	D · CT		Mar 27, 2025
Sen. Gallego, Ruben [D-AZ]	D · AZ		Mar 27, 2025
Sen. Hickenlooper, John W. [D-CO]	D · CO		Mar 27, 2025
Sen. King, Angus S., Jr. [I-ME]	I · ME		Mar 27, 2025
Sen. Klobuchar, Amy [D-MN]	D · MN		Mar 27, 2025
Sen. Reed, Jack [D-RI]	D · RI		Mar 27, 2025
Sen. Slotkin, Elissa [D-MI]	D · MI		Mar 27, 2025
Sen. Smith, Tina [D-MN]	D · MN		Mar 27, 2025
Sen. Welch, Peter [D-VT]	D · VT		Mar 27, 2025
Sen. Wyden, Ron [D-OR]	D · OR		Mar 27, 2025
Sen. Lujan, Ben Ray [D-NM]	D · NM		Apr 1, 2025

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 27, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
119 HR 2554	Related bill	Apr 1, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Lower Drug Costs for Families Act

This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance.

Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost \$100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties.

The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).

